Royalty Pharma Plc (RPRX) support and resistance · P/E 15, rev $1.30B
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
This page maps Royalty Pharma Plc (RPRX) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
RPRX currently screens at market cap $20.45B and trailing P/E 14.8. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new RPRX 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the RPRX quote page for the session range and the stock page for the full model.
Not investment advice.